PITTSBURGH -- (BUSINESS WIRE) -- RedPath Integrated Pathology, Inc., a leader in molecular diagnostics, announced the launch of a new, patent-pending, customized test to accurately measure carcinoembryonic antigen (CEA) in all pancreatic cyst fluids. Unlike routinely used, commercially available CEA assays, AccuCEA™ provides accurate results, even in pancreatic cyst fluid specimens with limited volume and/or high viscosity. Furthermore, AccuCEA provides physicians with more options in the diagnostic work-up of patients by preserving precious fluid and making it available for additional tests.
When the amount of pancreatic cyst fluid is limited and CEA testing is prescribed, CEA can be analyzed in diluted fluid. However, dilution of cyst fluid can significantly impact the analytical accuracy of the resulting CEA measurements. RedPath has solved this problem by creating AccuCEA, which provides CEA measurements in diluted cyst fluid that are true to their corresponding neat (undiluted) cyst fluid CEA measurements. Results of the study documenting the accuracy of AccuCEA were presented at the 2013 Digestive Disease Week meeting.
“Because improved imaging technologies now detect smaller and smaller pancreatic cysts from which physicians can aspirate fluid, the limited amount of fluid obtained may, in turn, limit diagnostic testing. The development and availability of AccuCEA resolves this dilemma by providing accurate CEA results on all diluted fluids and by allowing other tests to be ordered on the residual specimen.” said Dennis M. Smith, Jr., M.D., president and chief executive officer of RedPath Integrated Pathology.
About RedPath Integrated Pathology
RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory.
The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers. For more information about RedPath Integrated Pathology visit www.redpathip.com or contact Andrew Mignatti at 412-224-6100.